KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
The company's management will deliver a pre-recorded presentation available from 7:00 a.m. ET and participate in a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET. One-on-one meetings with management will be available throughout the conference.
KALA BIO (NASDAQ:KALA), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie innovative per le malattie oculari, parteciperà al 5° Congresso Annuale Virtuale di Oftalmologia H.C. Wainwright il 13 agosto 2025.
Il management dell'azienda presenterà una presentazione preregistrata disponibile a partire dalle 7:00 AM ET e prenderà parte a una tavola rotonda sul tema "Trattamenti Innovativi per le Patologie Anteriori dell'Occhio" alle 13:00 ET. Saranno inoltre disponibili incontri individuali con il management durante tutta la durata del congresso.
KALA BIO (NASDAQ:KALA), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar terapias innovadoras para enfermedades oculares, participará en la 5ª Conferencia Anual Virtual de Oftalmología de H.C. Wainwright el 13 de agosto de 2025.
La dirección de la compañía presentará una ponencia pregrabada disponible a partir de las 7:00 a.m. ET y participará en un panel sobre "Nuevos Tratamientos para Indicaciones en la Parte Frontal del Ojo" a la 1:00 p.m. ET. Se ofrecerán reuniones individuales con la dirección durante toda la conferencia.
KALA BIO (NASDAQ:KALA)는 혁신적인 안과 질환 치료제를 개발하는 임상 단계의 바이오제약 회사로서, 2025년 8월 13일에 개최되는 H.C. Wainwright 제5회 연례 안과 가상 컨퍼런스에 참여합니다.
회사의 경영진은 동부 표준시 기준 오전 7시부터 시청 가능한 사전 녹화 발표를 진행하며, 오후 1시에는 "눈 앞부분 질환을 위한 새로운 치료법" 패널 토론에 참여합니다. 컨퍼런스 기간 동안 경영진과의 일대일 미팅도 제공됩니다.
KALA BIO (NASDAQ:KALA), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies innovantes pour les maladies oculaires, participera à la 5e Conférence Annuelle Virtuelle d'Ophtalmologie H.C. Wainwright le 13 août 2025.
La direction de l'entreprise présentera une intervention préenregistrée disponible à partir de 7h00 ET et prendra part à une table ronde sur les « Nouveaux traitements pour les indications de la partie antérieure de l'œil » à 13h00 ET. Des réunions individuelles avec la direction seront également proposées tout au long de la conférence.
KALA BIO (NASDAQ:KALA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung innovativer Therapien für Augenerkrankungen spezialisiert hat, wird am 5. jährlichen virtuellen Ophthalmologie-Kongress von H.C. Wainwright am 13. August 2025 teilnehmen.
Das Management des Unternehmens wird eine vorab aufgezeichnete Präsentation ab 7:00 Uhr ET bereitstellen und an einer Podiumsdiskussion zum Thema „Neue Behandlungen für vordere Augenindikationen“ um 13:00 Uhr ET teilnehmen. Einzelgespräche mit dem Management werden während der gesamten Konferenz angeboten.
- None.
- None.
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday, August 13, 2025 at 7:00 a.m. ET. KALA management will also participate in a panel discussion titled “Novel Treatments for Front-of-the-Eye Indications” on Wednesday, August 13, 2025 at 1:00 p.m. ET. Management will be available for virtual one-on-one meetings throughout the conference.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When is KALA BIO presenting at the H.C. Wainwright Ophthalmology Conference 2025?
What panel discussion will KALA BIO participate in at the H.C. Wainwright conference?
How can investors access KALA BIO's H.C. Wainwright conference presentation?
What type of company is KALA BIO (NASDAQ:KALA)?
